natgillin/translations-raw huggingface dataset:
The combination of lenalidomide with melphalan and prednisone in clinical trials of newly diagnosed multiple myeloma patients is associated with a higher incidence of grade 4 neutropenia (34.1% in melphalan, prednisone and lenalidomide arm followed by lenalidomide [MPR+R] and melphalan, prednisone and lenalidomide followed by placebo [MPR+p] treated patients compared with 7.8% in MPp+p-treated patients; see section 4.8).
Kombinacija lenalidomida z melfalanom in prednizonom v kliničnih preskušanjih pri bolnikih z novo diagnosticiranim diseminiranim plazmocitomom je povezana z večjo incidenco nevtropenije 4. stopnje (34,1 % bolnikov v skupini z melfalanom, prednizonom in lenalidomidom, ki jim je sledil lenalidomid [MPR+R] in skupini z melfalanom, prednizonom in lenalidomidom, ki jim je sledil placebo [MPR+p], v primerjavi s 7,8 % bolnikov, zdravljenih z MPp+p; glejte poglavje 4.8).
The combination of lenalidomide with melphalan and prednisone in newly diagnosed multiple myeloma patients is associated with a higher incidence of grade 3 and grade 4 thrombocytopenia (40.4% in MPR+R/MPR+p treated patients, compared with 13.7% in MPp+p-treated patients).
Kombinacija lenalidomida z melfalanom in prednizonom pri bolnikih z novo diagnosticiranim diseminiranim plazmocitomom je povezana z večjo incidenco trombocitopenije 3. in 4. stopnje (40,4 % pri bolnikih, zdravljenih z MPR+R/MPR+p, v primerjavi s 13,7 % pri bolnikih, zdravljenih z MPp+p).
The combination of lenalidomide with melphalan and prednisone in newly diagnosed multiple myeloma patients is associated with a higher incidence of grade 4 neutropenia (34.1% in MPR+R/MPR+p compared with 7.8% in MPp+p).
Kombinacija lenalidomida z melfalanom in prednizonom pri bolnikih z novo diagnosticiranim diseminiranim plazmocitomom je povezana z večjo incidenco nevtropenije 4. stopnje (34,1 % pri MPR+R/MPR+p v primerjavi s 7,8 % pri MPp+p).
The combination of lenvatinib and everolimus showed increased antiangiogenic and antitumour activity as demonstrated by decreased human endothelial cell proliferation, tube formation, and VEGF signalling in vitro and tumour volume in mouse xenograft models of human renal cell cancer greater than each drug alone.
Kombinacija lenvatiniba in everolimusa je pokazala zvečanje antiangiogene in antitumorske aktivnosti, kar dokazuje zmanjšanje proliferacije humanih endotelijskih celic, nastajanja tubulov in signaliziranja z VEGF in vitro in volumna tumorjev v mišjih modelih ksenotransplantacije humanega raka ledvičnih celic, ki je bilo večje kot pri vsakem zdravilu posebej.
The combination of levodopa and carbidopa is used in other medicines for Parkinson’s disease.
Kombinacija levodope in karbidope se uporablja tudi v drugih zdravilih za Parkinsonovo bolezen.
The combination of linagliptin and metformin when administered in combination with insulin may be associated with an increased risk of hepatic events.
Pri sočasni uporabi kombinacije linagliptina in metformina z insulinom se lahko poveča tveganje jetrnih dogodkov.
The combination of lithium and Ifirmacombi is not recommended (see section 4.5).
Kombinacija litija in zdravila Ifirmacombi ni priporočena (glejte poglavje 4.5).
The combination of lithium and Ifirmasta is not recommended (see section 4.5).
Sočasno jemanje zdravila Ifirmasta in litija ni priporočljivo (gl. poglavje 4.5).
The combination of lithium and irbesartan is not recommended (see section 4.5).
Sočasna uporaba irbesartana in litija ni priporočljiva (glejte poglavje 4.5).
The combination of lithium and Irbesartan/Hydrochlorothiazide Teva is not recommended (see section 4.5).
Kombinacija litija in zdravila Irbesartan/hidroklorotiazid Teva ni priporočena (glejte poglavje 4.5).
The combination of lopinavir/ritonavir with atorvastatin is not recommended.
Uporaba lopinavirja/ritonavirja v kombinaciji z atorvastatinom ni priporočljiva.
The combination of lopinavir/ritonavir with:
Kombinacija lopinavirja/ritonavirja s:
The combination of macitentan with strong CYP3A4 inducers (e.g., rifampicin, St. John’s wort, carbamazepine, and phenytoin) should be avoided (see section 4.5).
Kombinaciji macitentana z močnimi induktorji CYP3A4 (npr. rifampicin, šentjanževka, karbamazepin in fenitoin) se je treba izogniti (glejte poglavje 4.5).
The combination of macitentan with strong CYP3A4 inducers should be avoided (see section 4.4).
Zato se je treba sočasni uporabi macitentana z močnimi induktorji CYP3A4 izogniti (glejte poglavje 4.4).
The combination of medicines to use and the duration of treatment will depend on the genotype (genetic make-up) of hepatitis C virus the patient is infected with and the nature of the patient’s liver problem, for example liver cirrhosis (scarring) or the liver not working well enough.
Uporabljena kombinacija zdravil in trajanje zdravljenja bosta odvisna od tega, s katerim genotipom (genetsko sestavo) virusa hepatitisa C je bolnik okužen in kakšne vrste težav z jetri ima – to je lahko na primer ciroza (brazgotinjenje) jeter ali njihovo nepravilno delovanje.
The combination of Neparvis with an ACE inhibitor is contraindicated due to the increased risk of angioedema (see section 4.3).
Kombinacija zdravila Neparvis z zaviralcem ACE je kontraindicirana, ker povečuje tveganje za angioedem (glejte poglavje 4.3).
The combination of Neparvis with direct renin inhibitors such as aliskiren is not recommended (see section 4.5).
Kombinacija zdravila Neparvis z neposrednim zaviralcem renina, kot je aliskiren, ni priporočena (glejte poglavje 4.5).
The combination of obinutuzumab with chlorambucil or bendamustine may increase neutropenia (see section 4.4).
Obinutuzumab v kombinaciji s klorambucilom ali bendamustinom lahko poveča delež nevtropenije (glejte poglavje 4.4).
The combination of Odefsey with these macrolide antibiotics may cause an increase in the plasma concentrations of rilpivirine (inhibition of CYP3A) and tenofovir alafenamide (inhibition of P-gp).
Kombinacija zdravila Odefsey s temi makrolidnimi antibiotiki lahko povzroči povečanje koncentracij rilpivirina (zaviranje encimov CYP3A) in alafenamidtenofovirata (zaviranje P-gp) v plazmi.
The combination of pimozide or quetiapine and EVOTAZ is contraindicated (see section 4.3).
Uporaba pimozida ali kvetiapina v kombinaciji z zdravilom EVOTAZ je kontraindicirana (glejte poglavje 4.3).
The combination of Remsima and abatacept is not recommended.
Kombiniranje zdravila Remsima in abatacepta torej ni priporočljivo.
The combination of Remsima with other biological therapeutics used to treat the same conditions as Remsima, including anakinra and abatacept, is not recommended (see section 4.4).
Kombiniranje zdravila Remsima z drugimi biološkimi zdravili za zdravljenje enakih bolezni kot z zdravilom Remsima, vključno z anakinro in abataceptom, ni priporočljivo (glejte poglavje 4.4).
The combination of REYATAZ with atorvastatin is not recommended (see section 4.5).
Zdravila REYATAZ ni priporočljivo uporabljati v kombinaciji z atorvastatinom (glejte poglavje 4.5).
The combination of Ribavirin BioPartners with interferon alfa-2b is used to treat adult patients with chronic hepatitis C, who have previously responded to a treatment with an alpha interferon alone, but whose condition has recurred.
Kombinacija zdravila Ribavirin BioPartners z interferonom alfa-2b se uporablja za zdravljenje odraslih bolnikov s kroničnim hepatitisom C, ki so se predhodno že odzvali na monoterapijo z enim samim interferonom alfa, a se jim je bolezen ponovila.
The combination of Ribavirin Teva Pharma B.V. with interferon alfa-2b is used to treat adult patients with chronic hepatitis C, who have previously responded to treatment with an alpha interferon alone, but whose condition has recurred.
Kombinacija zdravila Ribavirin Teva Pharma B.V. z interferonom alfa-2b se uporablja za zdravljenje odraslih bolnikov s kroničnim hepatitisom C, ki so se predhodno že odzvali na monoterapijo z enim od interferonov alfa samim, a se jim je bolezen ponovila.
The combination of Ribavirin Teva Pharma B.V. with interferon alfa-2b is used to treat patients 3 years of age and older who have chronic hepatitis C (HCV) infection.
Zdravilo Ribavirin Teva Pharma B.V. je namenjeno uporabi z interferonom alfa-2b za zdravljenje otrok starih 3 leta in več, ki imajo kronični hepatitis C (HCV).
The combination of rifampicin and
Kombinacija rifampicina in
The combination of rifapentine and
Kombinacija rifapentina in
The combination of saxagliptin 5 mg and dapagliflozin 10 mg in 1169 adults with type 2 diabetes mellitus (T2DM) and inadequate glycaemic control on metformin has been evaluated in three Phase 3, randomised, double-blind, active/placebo-control, parallel group, multi-centre clinical trials for up to 52 weeks (see section 5.1).
Kombinacijo 5 mg saksagliptina in 10 mg dapagliflozina so pri 1169 odraslih s sladkorno boleznijo tipa 2 (SBT2) in glikemijo, neustrezno urejeno z metforminom, ocenili v treh randomiziranih, dvojno slepih, z zdravilno učinkovino/placebom nadzorovanih multicentričnih kliničnih preskušanjih 3. faze z vzporednimi skupinami, ki so trajala do 52 tednov (glejte poglavje 5.1).
The combination of saxagliptin and dapagliflozin added to metformin consistently demonstrated greater reductions in HbA1c irrespective of baseline HbA1c compared with saxagliptin or dapagliflozin alone added to metformin.
Kombinacija saksagliptina in dapagliflozina, dodana metforminu, je HbA1c dosledno znižala bolj (ne glede na izhodiščni HbA1c) kot saksagliptin ali dapagliflozin, dodana metforminu vsak zase.
The combination of Simponi and abatacept is not recommended.
Kombiniranje zdravila Simponi in abatacepta torej ni priporočljivo.
The combination of such medicines together with Benlysta may make your immune system less effective.
Uporaba takšnih zdravil hkrati z zdravilom Benlysta lahko zmanjša učinkovitost vašega imunskega sistema.
The combination of telbivudine with any interferon alfa- containing product is contraindicated (see section 4.3).
Uporaba kombinacije telbivudina s katerimkoli zdravilom, ki vsebuje interferon alfa, je kontraindicirana (glejte poglavje 4.3).
The combination of telmisartan with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) and is not recommended in other patients (see sections 4.3, 4.4).
Uporaba kombinacije telmisartana in aliskirena je kontraindicirana pri bolnikih s sladkorno boleznijo ali ledvično okvaro (GFR < 60 ml/min/1,73 m2), pri drugih bolnikih pa je ne priporočajo (glejte poglavji 4.3, 4.4).
The combination of tenofovir disoproxil and emtricitabine has been approved as Truvada since 2005.
Kombinacija tenofovir-dizoproksila in emtricitabina je odobrena kot zdravilo Truvada od leta 2005.
The combination of the release profile and the dosage regimen (IM injection every two or four weeks) result in sustained olanzapine plasma concentrations.
Kombinacija profila sproščanja in režima odmerjanja (i.m. injiciranje vsake dva ali štiri tedne) vodi v podaljšane plazemske koncentracije olanzapina.
The combination of these effects reduces the activity of the brain and so causes unconsciousness.
S kombinacijo teh učinkov znižuje dejavnost možganov in tako povzroči nezavest.
The combination of these substances with complementary mechanisms of action provides an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.
Kombinacija teh dveh snovi s komplementarnimi mehanizmi delovanja omogoča aditiven antihipertenzivni učinek, ki zniža krvni tlak v večji meri kot vsaka od posameznih zdravilnih učinkovin samostojno.
The combination of this medicine, ribavirin and boceprevir is recommended for use for some types of chronic hepatitis C virus infection in adults 18 years of age and older (also called HCV infection).
Uporabo kombinacije tega zdravila z ribavirinom in boceprevirjem priporočamo pri nekaterih vrstah kronične okužbe z virusom hepatitisa C (imenovane tudi okužba HCV) pri odraslih, starih 18 let ali več.
The combination of Thymanax and alcohol is not advisable.
Sočasno jemanje zdravila Thymanax z alkoholom ni priporočljivo.
The combination of Valdoxan and alcohol is not advisable.
Sočasno jemanje zdravila Valdoxan z alkoholom ni priporočljivo.
The combination of vortioxetine with a reversible and selective MAO-A inhibitor, such as moclobemide, is contraindicated (see section 4.3).
Kombinacija vortioksetina z reverzibilnim in selektivnim zaviralcem MAO, kakršen je moklobemid, je kontraindicirana (glejte poglavje 4.3).
The combination of vortioxetine with a weak reversible and non-selective MAOI, such as the antibiotic linezolid, is contraindicated (see section 4.3).
Kombinacija vortioksetina s šibkim reverzibilnim in neselektivnim zaviralecem MAO, kakršen je antibiotik linezolid, je kontraindicirana (glejte poglavje 4.3).
The combination product lopinavir/ritonavir
kombinacija zdravil lopinavir/ritonavir
The combination product lopinavir/ritonavir (see section 4.5).
Kombinacija zdravil lopinavir/ritonavir (glejte poglavje 4.5).
The combination should be used with caution and a lower dose of trazodone should be considered.
Potrebna je previdnost in priporočljivo je nadziranje terapevtske koncentracije
The combination tablet was absorbed in the body in the same way as the separate medicines, when they were taken without food.
Kombinirana tableta se je po tkivih telesa porazdelila enako kot ločena zdravila, če so vzeta na prazen želodec.
The combination tablet was absorbed in the body in the same way as the separate tablets.
Kombinirana tableta se je v telesu absorbirala enako kot ločene tablete.
The combination umeclidinium and vilanterol was investigated in five main studies involving over 5,600 patients.
Kombinacijo umeklidinija in vilanterola so preučili v petih glavnih študijah, v katerih je sodelovalo več kot 5 600 bolnikov.
The combination umeclidinium bromide and vilanterol was investigated in four main studies involving over 4,700 patients.
Kombinacijo umeklidinijevega bromida in vilanterola so proučevali v štirih glavnih študijah, v katere je bilo vključenih 4 700 bolnikov.
The combination was effective for up to two years.
Kombinacija je bila učinkovita do dve leti.
The combination was generally
Kombinacijo so na splošno
The combination was generally well
Kombinacijo so na splošno
The combinations of emtricitabine, rilpivirine, and tenofovir alafenamide were not antagonistic and showed synergistic effects with each other in cell culture combination antiviral activity assays.
Kombinacija emtricitabina, rilpivirina in alafenamidtenofovirata ni bila antagonistična in dokazana je bila sinergijska protivirusna aktivnost v celični kulturi.
The combined action of aliskiren and amlodipine on these two central blood pressure-regulating factors (vasoconstriction and RAAS-mediated hypertensive effects) results in more effective antihypertensive effects than seen with monotherapy.
Kombinacija delovanja aliskirena in amlodipina na oba omenjena dejavnika za uravnavanje centralnega krvnega tlaka (na vazokonstrikcijo in na hipertenzivne učinke preko sistema RAAS) omogoča bolj učinkovito antihipertenzivno delovanje kot vsaka od zdravilnih učinkovin samostojno.
The combined action of the two active substances helps to keep the airways open and allows the patient to breathe more easily.
Kombinirano delovanje teh dveh zdravilnih učinkovin pomaga pri vzdrževanju odprtih dihalnih poti in bolniku omogoča lažje dihanje.
The combined results of these two trials are presented below:
Rezultati obeh študij so prikazani v preglednici:
The combined use of alcohol, or any CNS -depressant medicinal product, with sodium oxybate may result in potentiation of the CNS-depressant effects of sodium oxybate as well as increased risk of respiratory depression.
Pri sočasni uporabi alkohola ali katerega koli zaviralca centralnega živčnega sistema z natrijevim oksibatom se lahko okrepijo zaviralni učinki natrijevega oksibata na centralni živčni sistem.
The combined use of Aptivus, co-
Kombinirane uporabe zdravila
The combined use of fluoroquinolones with digoxin should also be avoided because of potentially increased oral bioavailability of digoxin.
Prav tako pa se je potrebno izogibati hkratni uporabi fluorokinolonov in digoksina, zaradi morebitnega povečanja oralne bio- razpoložljivosti digoksina.
The combined use of Rapamune with angiotensin-converting enzyme (ACE) inhibitors (a type of medicine used to lower blood pressure) may result in allergic reactions.
Uporaba zdravila Rapamune sočasno z zaviralci angiotenzinske konvertaze (ACE) (vrsta zdravila, ki se uporablja za zniževanje krvnega tlaka) lahko povzroči alergijske reakcije.
the Commission
za promet, da bi
The Committee also acknowledged that there is an unmet medical need for these patients.
Odbor je prav tako potrdil, da obstaja neizpolnjena potreba po zdravilu za te bolnike.
The Committee also acknowledged the seriousness of Duchenne muscular dystrophy and the unmet medical need of patients with this condition.
Prav tako je odbor izpostavil resnost Duchennove mišične distrofije in neizpolnjeno potrebo po zdravilu za bolnike s to boleznijo.
The Committee also concluded that the data derived from the COPD studies adequately demonstrated that Relvar Ellipta 92 /22 microgram had a clinically relevant effect on the reduction of COPD flare-ups.
Prav tako je zaključil, da so podatki, zbrani v študijah kronične obstruktivne pljučne bolezni, v zadostni meri pokazali, da ima zdravilo Relvar Ellipta 92 /22 mikrogramov klinično pomemben učinek na zmanjšanje izbruhov kronične obstruktivne pljučne bolezni.
The Committee also concluded that the data derived from the COPD studies adequately demonstrated that Revinty Ellipta 92 /22 microgram had a clinically relevant effect on the reduction of COPD flare-ups.
Prav tako je zaključil, da so podatki, zbrani v študijah kronične obstruktivne pljučne bolezni, v zadostni meri pokazali, da ima zdravilo Revinty Ellipta 92 /22 mikrogramov klinično pomemben učinek na zmanjšanje izbruhov kronične obstruktivne pljučne bolezni.
The Committee also considered that the benefit of Truvada has been shown for pre-exposure prophylaxis but the level of protection depends on how well individuals stick to the recommended dose schedule.
Odbor je tudi menil, da so bile koristi zdravila Truvada za predekspozicijsko profilakso dokazane, da pa je raven zaščite odvisna od tega, kako dosledno oseba upošteva shemo priporočenih odmerkov.
The Committee also considered that the benefits of Invega had been shown to be greater than its risks in the treatment of schizophrenia in adolescents from 15 years of age.
Prav tako je menil, da je bilo dokazano, da so koristi zdravila Invega večje od z njim povezanih tveganj pri zdravljenju shizofrenije pri mladostnikih, starejših od 15 let.
The Committee also considered that the data available support the use of Olysio in combination with sofosbuvir.
Odbor je zato menil, da razpoložljivi podatki podpirajo uporabo zdravila Olysio v kombinaciji s sofosbuvirjem.
The Committee also considered that, if given before a liver transplant, Sovaldi in combination with ribavirin can prevent re-infection of the liver, which in the absence of treatment occurs nearly always and results in a poor prognosis.
Odbor je prav tako menil, da lahko dajanje zdravila Sovaldi v kombinaciji z ribavirinom pred presaditvijo jeter prepreči ponovno okužbo jeter, ki se brez zdravljenja pojavi skoraj vedno in prispeva k slabi prognozi.
The Committee also considered the fact that Zytiga is given by mouth to be a further advantage.
Poleg tega je menil, da je dejstvo, da se zdravilo Zytiga jemlje peroralno, dodatna prednost.
The Committee also noted that Activyl Tick Plus combined two active substances thereby reducing the need to use two different products against flea and tick infestations.
Odbor je nadalje opozoril, da zdravilo Activyl Tick Plus združuje dve učinkovini ter s tem zmanjšuje potrebo po uporabi dveh različnih zdravil proti infestacijam z bolhami in klopi.
The Committee also noted that for patients with homozygous familial disease there is an unmet clinical need, as these patients are difficult to treat and have a high risk of cardiovascular disease.
Odbor je prav tako izpostavil, da je pri bolnikih s homozigotno družinsko boleznijo prisotna neizpolnjena klinična potreba, saj je te bolnike težko zdraviti in imajo veliko tveganje za pojav srčno-žilnih bolezni.
The Committee also noted that patients with CLL who had not responded to previous treatment have limited treatment options.
Prav tako je poudaril, da imajo bolniki s kronično limfocitno levkemijo, ki se niso odzvali na predhodna zdravljenja, omejene možnosti zdravljenja.
The Committee also noted that short bowel syndrome is a serious and disabling condition for which only limited symptomatic treatment exists.
Odbor je tudi opozoril, da je sindrom kratkega črevesa resna motnja, ki bolnika onesposablja in za katero obstaja le omejeno simptomatsko zdravljenje.
The Committee also noted that tazobactam is known not to be active against some classes of beta-lactamase that can cause problems of resistance.
Prav tako je izpostavil, da je znano, da tazobaktam ne deluje proti določenim vrstam betalaktamaz, ki lahko povzročijo težave z odpornostjo.
The Committee also noted that the demonstration of Atripla’s benefit is based mainly on 48-week data from a study in patients with stable suppression of HIV on an HIV treatment combination who then switched to Atripla.
Odbor je opazil tudi, da prikaz koristi zdravila Atripla temelji zgolj na podatkih iz 48-tedenske študije pri bolnikih s stabilno supresijo virusa HIV, ki so pred prehodom na zdravilo Atripla že prejemali kombinirana zdravila proti okužbi z virusom HIV.
The Committee also noted that the safety profile of Imnovid was considered acceptable for these patients, with side effects similar to those of other medicines of this type.
Prav tako je ugotovil, da je varnostni profil zdravila Imnovid za te bolnike sprejemljiv, neželeni učinki pa so podobni učinkom drugih tovrstnih zdravil.
The Committee also noted that the World Health Organization continues to recommend PAS as an option to be used in combination with other medicines for treating multi-drug resistant tuberculosis.
Odbor je prav tako ugotovil, da Svetovna zdravstvena organizacija še naprej priporoča para- aminosalicilno kislino kot možnost za uporabo v kombinaciji z drugimi zdravili za zdravljenje tuberkuloze, odporne proti več zdravilom.
The Committee also noted that there is little information on the benefits of treatment including a protease inhibitor in patients who have been treated with Stocrin in the past but which stopped working, although there is no evidence to suggest that protease inhibitors may not work in these patients.
Poudaril je tudi, da je malo informacij o koristih zdravljenja z zaviralcem proteaze pri bolnikih, ki so bili v preteklosti zdravljeni z zdravilom Stocrin, ki je prenehalo biti učinkovito, čeprav ni dokazov, da zaviralci proteaze pri teh bolnikih ne bi bili učinkoviti.
The Committee also noted that there is little information on the benefits of treatment including a protease inhibitor in patients who have been treated with Sustiva in the past but which stopped working, although there is no evidence to suggest that protease inhibitors may not work in these patients.
Poudaril je tudi, da je malo informacij o koristih zdravljenja z zaviralcem proteaze pri bolnikih, ki so bili v preteklosti zdravljeni z zdravilom Sustiva, ki je prenehalo biti učinkovito, čeprav ni dokazov, da zaviralci proteaze pri teh bolnikih ne bi bili učinkoviti.
The Committee also noted that treatment with Firmagon does not trigger the temporary sharp rise in testosterone levels seen with ‘GnRH agonists’ (other medicines for prostate cancer that stimulate the production of GnRH).
Odbor je prav tako ugotovil, da zdravljenje z zdravilom Firmagon ne sproži začasnega hitrega dviga koncentracije testosterona, ki je značilna za „agoniste gonadotropin sproščujočega hormona“ (druga zdravila za raka prostate, ki spodbujajo tvorjenje gonadotropin sproščujočega hormona).
The Committee also noted that with Plenadren there is the convenience of once daily dosing.
Odbor je pripomnil tudi, da je zdravilo Plenadren prikladno za jemanje, saj je potrebno le eno odmerjanje zdravila dnevno.